Clinical effects of CYP2D6 phenoconversion in patients with psychosis
Polypharmacy and phenoconversion were prevalent and accounted for a significant increase in PMs. CYP2D6 may play a limited role in side effects, symptoms and well-being measures. However, due to the high frequency of occurrence, phenoconversion should be considered in future clinical trials.
Authors
- Roos van Westrhenen (ORCID: https://orcid.org/0000-0003-2298-9924)
- Thérèse van Amelsvoort (ORCID: https://orcid.org/0000-0003-1135-5133)
- Emma Y De Brabander (ORCID: https://orcid.org/0000-0002-0057-750X)
- Esmee Breddels
Institutions
- Radboud University Nijmegen (NL)
- King's College London (GB)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Parnassia Groep (NL)
- St. John's National Academy of Health Sciences (IN)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1177/02698811241278844
- Citations
- 2
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Horizon 2020 Framework Programme